1-14 of 14
Carlos L. Arteaga
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer

Yaru Xu, Yuqiu Yang, Zhaoning Wang, Martin Sjöström, Yuyin Jiang, Yitao Tang, Siyuan Cheng, Su Deng, Choushi Wang, Julisa Gonzalez, Nickolas A. Johnson, Xiang Li, Xiaoling Li, Lauren A. Metang, Atreyi Mukherji, Quanhui Xu, Carla R. Tirado, Garrett Wainwright, Xinzhe Yu, Spencer Barnes, Mia Hofstad, Yu Chen, Hong Zhu, Ariella B. Hanker, Ganesh V. Raj, Guanghui Zhu, Housheng H. He, Zhao Wang, Carlos L. Arteaga, Han Liang, Felix Y. Feng, Yunguan Wang, Tao Wang, Ping Mu
Journal: Cancer Discovery
Cancer Discov (2024) 14 (8): 1496–1521.
https://doi.org/10.1158/2159-8290.CD-23-0539
Published: 02 August 2024
View article titled, ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Open the PDF for ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients

Carlos L. Arteaga, John L. Cleveland, Margaret Foti, Ruben A. Mesa, Louis M. Weiner, Cheryl L. Willman, David A. Tuveson
Journal: Cancer Discovery
Cancer Discov (2023) 13 (11): 2316–2318.
https://doi.org/10.1158/2159-8290.CD-23-0988
Published: 01 November 2023
View article titled, AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Open the PDF for AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients in another window
Journal Articles

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Otto Metzger Filho, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell'Orto, Leila Russo, Tari A. King, Kornelia Polyak, Franziska Michor, Eric P. Winer, Ian E. Krop
Journal: Cancer Discovery
Cancer Discov (2021) 11 (10): 2474–2487.
https://doi.org/10.1158/2159-8290.CD-20-1557
Published: 01 October 2021
View article titled, Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Open the PDF for Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab in another window
Includes: Supplementary data
Journal Articles

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Lillian M. Smyth, Sarina A. Piha-Paul, Helen H. Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos L. Arteaga, Macarena I. de la Fuente, Adam M. Brufksy, Iben Spanggaard, Morten Mau-Sørensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S. Schwartzberg, Xavier Gonzàlez-Farré, Andrés Cervantes, François-Clement Bidard, Alexander N. Gorelick, Richard B. Lanman, Rebecca J. Nagy, Gary A. Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I. Gavrila, Catherine Zimel, S. Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D. Eli, Melanie Dujka, Alshad S. Lalani, Richard Bryce, José Baselga, Barry S. Taylor, David B. Solit, Funda Meric-Bernstam, David M. Hyman
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (2): 198–213.
https://doi.org/10.1158/2159-8290.CD-19-0966
Published: 05 February 2020
View article titled, Efficacy and Determinants of Response to HER Kinase Inhibition in <em>HER2</em>-Mutant Metastatic Breast Cancer
Open the PDF for Efficacy and Determinants of Response to HER Kinase Inhibition in <em>HER2</em>-Mutant Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

Ariella B. Hanker, Virginia Kaklamani, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2019) 9 (4): 482–491.
https://doi.org/10.1158/2159-8290.CD-18-1175
Published: 01 April 2019
View article titled, Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
Open the PDF for Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors in another window
Journal Articles

Correction: Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

Angel L. Guerrero-Zotano, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2019) 9 (2): 304.
https://doi.org/10.1158/2159-8290.CD-18-1516
Published: 08 February 2019
View article titled, Correction: Neoadjuvant Trials in ER<sup>+</sup> Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
Open the PDF for Correction: Neoadjuvant Trials in ER<sup>+</sup> Breast Cancer: A Tool for Acceleration of Drug Development and Discovery in another window
Journal Articles

Correction: An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca Nagy, Richard Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent Miller, Richard E. Cutler, Jr, Alshad S. Lalani, Darren Cross, Christine M. Lovly, Jens Meiler, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2019) 9 (2): 303.
https://doi.org/10.1158/2159-8290.CD-18-1515
Published: 08 February 2019
View article titled, Correction: An Acquired <em>HER2</em><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Open the PDF for Correction: An Acquired <em>HER2</em><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer in another window
Journal Articles

Correction: Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy

Thomas Stricker, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2019) 9 (2): 302.
https://doi.org/10.1158/2159-8290.CD-18-1514
Published: 08 February 2019
View article titled, Correction: Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy
Open the PDF for Correction: Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy in another window
Journal Articles

An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca Nagy, Richard Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent Miller, Richard E. Cutler, Jr, Alshad S. Lalani, Darren Cross, Christine M. Lovly, Jens Meiler, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2017) 7 (6): 575–585.
https://doi.org/10.1158/2159-8290.CD-16-1431
Published: 01 June 2017
View article titled, An Acquired <em>HER2</em> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Open the PDF for An Acquired <em>HER2</em> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery

Angel L. Guerrero-Zotano, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2017) 7 (6): 561–574.
https://doi.org/10.1158/2159-8290.CD-17-0228
Published: 01 June 2017
View article titled, Neoadjuvant Trials in ER<sup>+</sup> Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
Open the PDF for Neoadjuvant Trials in ER<sup>+</sup> Breast Cancer: A Tool for Acceleration of Drug Development and Discovery in another window
Journal Articles

Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy

Thomas Stricker, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2015) 5 (11): 1124–1126.
https://doi.org/10.1158/2159-8290.CD-15-1166
Published: 01 November 2015
View article titled, Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy
Open the PDF for Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy in another window
Journal Articles

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Justin M. Balko, Jennifer M. Giltnane, Kai Wang, Luis J. Schwarz, Christian D. Young, Rebecca S. Cook, Phillip Owens, Melinda E. Sanders, Maria G. Kuba, Violeta Sánchez, Richard Kurupi, Preston D. Moore, Joseph A. Pinto, Franco D. Doimi, Henry Gómez, Dai Horiuchi, Andrei Goga, Brian D. Lehmann, Joshua A. Bauer, Jennifer A. Pietenpol, Jeffrey S. Ross, Gary A. Palmer, Roman Yelensky, Maureen Cronin, Vincent A. Miller, Phillip J. Stephens, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2014) 4 (2): 232–245.
https://doi.org/10.1158/2159-8290.CD-13-0286
Published: 04 February 2014
View article titled, Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Open the PDF for Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets in another window
Includes: Supplementary data
Journal Articles

BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors

Anthony C. Faber, Ryan B. Corcoran, Hiromichi Ebi, Lecia V. Sequist, Belinda A. Waltman, Euiheon Chung, Joao Incio, Subba R. Digumarthy, Sarah F. Pollack, Youngchul Song, Alona Muzikansky, Eugene Lifshits, Sylvie Roberge, Erik J. Coffman, Cyril H. Benes, Henry L. Gómez, José Baselga, Carlos L. Arteaga, Miguel N. Rivera, Dora Dias-Santagata, Rakesh K. Jain, Jeffrey A. Engelman
Journal: Cancer Discovery
Cancer Discov (2011) 1 (4): 352–365.
https://doi.org/10.1158/2159-8290.CD-11-0106
Published: 14 September 2011
View article titled, BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
Open the PDF for BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors in another window
Includes: Multimedia, Supplementary data
Journal Articles

ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

Todd W. Miller, Justin M. Balko, Emily M. Fox, Zara Ghazoui, Anita Dunbier, Helen Anderson, Mitch Dowsett, Aixiang Jiang, R. Adam Smith, Sauveur-Michel Maira, H. Charles Manning, Ana M. González-Angulo, Gordon B. Mills, Catherine Higham, Siprachanh Chanthaphaychith, Maria G. Kuba, William R. Miller, Yu Shyr, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2011) 1 (4): 338–351.
https://doi.org/10.1158/2159-8290.CD-11-0101
Published: 14 September 2011
View article titled, ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Open the PDF for ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer in another window
Includes: Supplementary data